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and European countries. Methods: Comparison of miligram based prices analy-
sis between European countries done by Intelligent Health System(IHS) was used. 
The analysis of IHS included Germany, France, United Kingdom(UK), Spain and 
Italy(EU5). Comparison was done with taken row data of analysis EU5 and Turkey 
average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, 
Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine 
molecules. Results: It has been reported that compared 10 molecules highest 
average miligram based prices of Esomeprazole(0,043 € ), Levofloxacin(0,058 € ) and 
Clopidogrel(0,0083 € ) molecules belong to Turkey, Lamotrigine(0,01 € ) belongs to 
Germany. The highest average miligram based prices of other 6 molecules belong 
to UK with following; Ceftriaxone(0,0196 € ), Fentanyl(0,186 € ), Letrozole(1,24 € ), 
Metformine(0,00013 € ), Venlafaxine(0,0074 € ), Olanzapine(0,261 € ). ConClusions: 
It has known that because of UK used free pricing mechanism on drugs, prices of 
drugs are higher than other compared countries. This sitiuation established on the 
anaylsis. But despite of Turkish Government policy decisions; it is important indicia-
tion that 3 drugs represents highest prices out 10 drugs. Reference pricing system 
applied based on box price. Better control mechanism may achievable if miligram 
based pricing apply in Turkey. On the other hand because of the study only consist 
retail sales prices the evaluation should be done from point of reimbursement 
prices on future studies.
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objeCtives: The expiration of biotech drugs patent has led to the creation of drugs 
copies of originator products, defined ‘biosimilars’. No European country allows 
automatic substitution between the originator and the biosimilar. In Italy, due to 
the lack of a national legislation, some Regions have issued directives to encour-
age the use of biosimilars, recognizing a potential saving of resources. Campania 
Region was the first region to legislate on the matter, (decree no. 15 of 11.30.2009) 
supporting the prescription of biosimilars to the naive patient. The aim of our 
study is to describe trends in biosimilars consumption in Campania region and 
evaluate how biosimilar products are replacing the originators in the respective 
markets. Methods: IMS Health regional database was used to analyze biosimi-
lar drugs consumption patterns (erythropoietins, G-CSF, somatropin) in the years 
2009- 2012. Information was retrieved about different distribution channels (retail, 
direct distribution, hospital). Consumptions are expressed in Counting Units (CU) 
and trends have been calculated using Compound Average Grow Rate (CAGR). The 
study especially focused on consumption trends of erythropoietin (ATC B03XA) in 
the years 2009-2012. Results: In 2012 the penetration rate of biosimilars was 40.1% 
(evaluated as the biosimilars share of the total erythropoietins, G-CSF, somatropin 
market). These values are double than those at national level, that are estimated to 
be 19.7% of consumption. Focus on erythropoietin trends showed a strong increase 
in biosimilars consumption (451 CU in 2009 vs 140,327 CU in 2012) after the introduc-
tion of regional measures to promote the prescription of biosimilars to the naive 
patient. In 2012, biosimilar erythropoietins and reference drugs show similar market 
shares (37.0% and 33.7% of the total erythropietins market respectively) showing 
a high substitution effect. ConClusions: Our analysis outlines the significant 
effects of regional measures on market penetration rates of biosimilars.
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objeCtives: Estimation of the direct and indirect savings generated by parallel 
importing (PI) of pharmaceutical products in public pharmacies in Poland, and esti-
mation of the savings for the payer in the case of reimbursed drugs. Methods: IMS 
Health Poland National Sales Data (2005-2012) and data from respective reimburse-
ment lists were used for all calculations. Direct savings were estimated considering 
all PI products sold in public pharmacies(433 products, 1550 SKUs). To avoid overes-
timation, only 18 products that passed restrictive criteria were used for calculations 
of indirect savings. Twenty-seven reimbursed products were used for the payer 
savings calculations. Direct savings were calculated as a difference between PI and 
reference product prices multiplied by the number of packs of PI product. Indirect 
savings were calculated as a difference between the reference product price and 
the theoretical reference product price (i.e. prices in a hypothetical situation where 
there is no price pressure caused by PI – calculated using linear regression). Indirect 
savings considered only those products which met the criteria of the reference 
product’s price decrease of at least 5% within 3 months prior to, or after, the appear-
ance of the PI product. Results: Study revealed that the savings generated by the 
PI of pharmaceuticals in Poland between 2005-2012 may be estimated at the level 
of EUR 146m (direct savings EUR 46m and indirect savings EUR 100m). Savings for 
the payer calculated for reimbursed products between 2008-2012 reached the level 
of EUR 0.06m. ConClusions: This is the first study estimating direct and indirect 
savings coming from PI phenomena covering all years since PI was reinforced by 
Poland’s accession to the EU. It has been found very interesting that indirect sav-
ings tend to be substantially higher that direct ones. This indicates that high price 
pressure is created by PI, and affects the prices of reference products.
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assessment outcomes, 2) analyze correlations between additional benefit, budget 
impact and negotiated rebate. Methods: To achieve objective 1, assessments by 
the GBA and the IQWiG (Institute for Quality and Efficiency in Healthcare) (source: 
GBA website) were scanned for key trends. To achieve objective 2, list and post-
negotiation prices were extracted from the Lauer-Taxe (German price database). 
For the 10 agents that had so far completed price negotiations, these were mapped 
against additional benefit and the budget impact (annual therapy costs as stated 
in GBA assessment). Results: The results linked to objective 1, which were more 
qualitative in nature, allowed for the extraction of 5 key learnings for manufacturers 
to keep in mind. The results associated with objective 2 showed no link between 
additional benefits granted and negotiated rebate but did reveal price impacting 
parameters apart from budget impact. ConClusions: Concerning objective 1, the 
ways in which manufacturers can attempt to optimize benefit outcomes include: 1. 
Focus on comparator choice, 2. Focus on hard endpoints, 3. Make patient segmenta-
tion more solid, 4. Expect independent action of GBA and IQWiG and 5. Accept that 
there is no methodological standard for the definition of an additional benefit. 
Regarding objective 2, we concluded that budget impact, influenced primarily by 
target population size, annual therapy costs and drug price, is an – if not the most 
important driver in the negotiation.
PHP22
is Drug innovation still rewarDeD in tHe toP 5 euroPean 
PHarmaCeutial markets?
Reinaud F.1, Ando G.2
1IHS, Paris, France, 2IHS, London, UK
objeCtives: To assess how drug innovation is rewarded and how it is impacted 
by cost-containment policies. Methods: Manufacturer prices per unit of pack-
age and strengths were compared and assessed in a basket of 97 innovative drugs 
approved by the European Medicines Agency (EMA) since 2000. The products were 
still patent protected, and available in each of the top 5 European pharmaceutical 
markets. Results: Prices of innovative drugs in Germany were still the highest and 
had a benchmark price index of 100. In France, when drugs were deemed innova-
tive, premium prices were granted – resulting in a price index of 94 – but signifi-
cantly decreased over time. While prices at launch in Italy, Spain and the UK were 
commonly lower – with price indexes of 89, 88 and 86 respectively - they tended 
to remain constant over time. ConClusions: Despite the fact that governments 
in developed markets are attempting to lower prices, differences still exist across 
the largest markets, enabling pharmaceutical companies to implement differential 
and protective pricing strategies. In Germany, time to market is comparatively fast 
and premium prices at launch have been granted. In future, the AMNOG reform 
will complicate this picture, although pricing premiums have still been achieved 
for drugs deemed innovative that have gone through the full AMNOG process. In 
France, although prices are relatively high at launch, they drop at time of renewal 
and innovation is granted to a limited number of drugs. Prices have been compara-
tively low at launch but remain constant in Italy and Spain, reflecting the fact that 
price cuts in those countries have often been directed towards generics, although 
these are still considered high-risk markets. In the UK, it remains to be seen how 
the value-based pricing reform will impact prices.
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objeCtives: To describe availability of orphan drugs in France, UK and Germany and 
to compare agencies’ assessments and prices. Methods: All the products designated 
as orphan drugs by the European Commission and commercialized at least in one of 
the three countries were included in the study. Comparison of prices is made per dos-
age and is based on prices per standard unit, using IMS MIDAS database. Comparison 
of assessments is based on Transparency Committee opinions, NICE guidances and 
IQWIG benefit assessments. Results: Sixty-two products (103 dosages/forms) were 
included in this study; 47 (76%; 84 dosages/forms) are commercialized in the 3 coun-
tries, 8 (13%) products in only 2 countries (6 both in Germany and UK and 2 both in 
Germany and France) and 7 (11%) only in 1 country (6 in Germany only and 1 in France 
only). Among the 84 products/dosage/forms available in the three countries, most of 
them are available at hospital (respectively 68, 70 and 77 in Germany, France and UK) 
but those available through retail pharmacists are much numerous in Germany (72 of 
them) than in France (29) or UK (30). German and UK manufacturer March 2013 retail 
prices more often higher than French one, despite the fact that among the 49 orphan 
drugs commercialized in France, 31 are innovative products (ASMR rate I to III). For 
instance, French assessment of pirfenidone was less favorable than the Germans’one, 
and German price is thus +65.2% higher than French price. French and UK HTA assess-
ments for azacitidine were both positive and led to similar prices. ConClusions: 
Most orphan drugs are available in the three studied countries but accessibility to 
them seems to be different and depends on HTA results.
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objeCtives: The reference pricing system is used for setting drug prices in Turkey 
since 2006. There are 5 reference countries following; Spain, Italy, Germany, France 
and Greece. Except those countries, manufactured or imported countries may be 
used as reference countries. Reference prices are reviewed time by time and may 
be subject to certain alterations, but evaluation of box prices may be different if 
evaluation made based on milligram. The aim of this study is to evaluate differ-
ences of average milligram sales prices of some generic medicines between Turkey 
